HLS Therapeutics Inc.

TSX:HLS.TO

3.37 (CAD) • At close November 13, 2024
Overview | Financials

Numbers are in millions (except for per share data and ratios) CAD.

2023202220212020201920182017201620152014201320122011201020092008200720062005200420032002200120001999199819971996
Revenue 63.07461.46760.00956.10954.1661.41575.08254.03119.95673.87779.466116.55678.74688.09971.87668.147100.58949.66168.20277.80983.21435.5233.2599.83295.627101.31976.2459.653
Cost of Revenue 7.6244.9813.9723.6251.9322.5954.136-0.104-0.21553.02962.50691.42658.2470.44661.2156.64881.86346.45363.88573.18174.11529.89527.52494.6788.86198.39573.65558.243
Gross Profit 55.4556.48656.03752.48452.22858.8270.94654.13520.17120.84816.9625.1320.50617.65310.66611.49918.7263.2084.3174.6289.0995.6255.7275.1626.7662.9252.5861.41
Gross Profit Ratio 0.8790.9190.9340.9350.9640.9580.9451.0021.0110.2820.2130.2160.260.20.1480.1690.1860.0650.0630.0590.1090.1580.1720.0520.0710.0290.0340.024
Reseach & Development Expenses 0000000000000000000000000000
General & Administrative Expenses 8.3917.73517.39718.48518.0914.46311.8771.362.6814.6824.4853.1460000000000000000
Selling & Marketing Expenses 19.89617.84614.6612.96.2564.3233.5513.2012.5380000000000000000000
SG&A 28.28635.58132.05731.38524.34618.78615.4281.362.6814.6824.4853.1463.853000000.021000000000
Other Expenses 37.51334.40230.26433.18632.5132.39532.2330.0030.03-0.018000.28112.4446.6070.11-0.1141.04310.7033.6583.8642.1292.2282.5692.8311.560.6290.371
Operating Expenses 65.79969.98362.32164.57156.85651.18147.6611.362.6814.6824.4853.1464.13412.4446.6074.2166.7321.8182.4783.6583.8642.1292.2282.5692.8311.560.6290.371
Operating Income -10.349-13.44-6.24-11.256-4.0437.63923.285-1.256-2.46616.16612.47621.98416.45817.6534.0594.44712.0691.35-0.1440.9695.2353.4963.4992.5923.9361.3651.9571.039
Operating Income Ratio -0.164-0.219-0.104-0.201-0.0750.1240.31-0.023-0.1240.2190.1570.1890.2090.20.0560.0650.120.027-0.0020.0120.0630.0980.1050.0260.0410.0130.0260.017
Total Other Income Expenses Net -17.454-10.225-5.524-4.212-15.835-36.442-24.43-27.939-2.5330.8250.3470.591-0.04-10.54-0.776-8.409-1.1350.39610.352-10.315-0.5420.7960.787-0.0420.053-7.1490.769-0.223
Income Before Tax -27.803-23.722-11.808-16.299-20.463-28.803-1.145-1.039-2.21716.99212.82222.57516.4181.6663.282-3.96210.9341.74710.208-8.5314.6924.2914.2862.555.662-5.8492.6550.816
Income Before Tax Ratio -0.441-0.386-0.197-0.29-0.378-0.469-0.015-0.019-0.1110.230.1610.1940.2080.0190.046-0.0580.1090.0350.15-0.110.0560.1210.1290.0260.059-0.0580.0350.014
Income Tax Expense -0.272-0.1241.309-0.968-0.911-3.9974.952-0.164-0.4854.2743.095.7084.0882.40.7291.6793.3390.4370.7010.1571.8041.3441.3771.1461.1050.780.908-0.445
Net Income -27.531-23.598-13.117-15.331-19.552-24.806-6.097-0.875-1.73212.7179.73316.86711.983-0.7342.554-5.6417.5951.319.507-8.6892.8882.9472.9092.2884.074-6.6291.7476.9
Net Income Ratio -0.436-0.384-0.219-0.273-0.361-0.404-0.081-0.016-0.0870.1720.1220.1450.152-0.0080.036-0.0830.0760.0260.139-0.1120.0350.0830.0870.0230.043-0.0650.0230.116
EPS -0.85-0.73-0.41-0.48-0.67-0.92-0.24-0.035-0.0980.650.490.830.6-0.0320.11-0.220.330.060.46-0.460.150.130.180.210.39-0.690.231.03
EPS Diluted -0.85-0.73-0.41-0.48-0.67-0.92-0.24-0.035-0.0980.650.490.820.6-0.0320.11-0.220.330.060.46-0.460.150.130.180.210.37-0.690.231.03
EBITDA 12.88417.99725.41223.19419.74620.70255.51838.242-2.46620.01418.46429.19322.29214.10511.0068.66318.7263.2084.2974.6289.0995.6255.7275.1626.7662.9252.5161.41
EBITDA Ratio 0.2040.3410.40.3910.5260.3490.741-0.023-0.1240.2650.2350.250.2830.1310.1530.1270.1850.0650.0920.0590.1090.1580.1720.0520.0710.0290.0340.024